In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: Israeli startup to use AI to transform antibody discovery, design
Israeli startup to use AI to transform antibody discovery, design
Israel’s AION Labs announced last week the launch of CombinAble.AI, a startup focused on improving antibody design to speed up the development of better therapeutics.
Visit: AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
Yahoo! Finance
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
Visit: AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
PR Newswire
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
Visit: New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
PharmiWeb
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.
Visit: New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Healthcare Industry Baden Württemberg (powered by BioPro)
BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON). The main objective of…
Visit: New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Yahoo! Finance
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.